Eliana Merle
Stock Analyst at UBS
(0)
# 3907
Out of 5,240 analysts
84
Total ratings
34.15%
Success rate
-2.97%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Revolution Medicines | Maintains: Strong Buy | 65 71 | 39.85 | 78.17% | 2 | Jan 8, 2025 | |
Moderna | Maintains: Buy | 108 96 | 34.47 | 178.5% | 5 | Jan 8, 2025 | |
Ascendis Pharma | Initiates Coverage On: Buy | 196 | 131.53 | 49.02% | 1 | Jan 7, 2025 | |
Tyra Biosciences | Initiates Coverage On: Buy | 28 | 15.96 | 75.44% | 1 | Jan 7, 2025 | |
Sagimet Biosciences | Initiates Coverage On: Buy | 12 | 4.12 | 191.26% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 3 | 2.11 | 42.18% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 26 | 6.22 | 318.01% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 80 74 | 40.09 | 84.58% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 411 441 | 274.16 | 60.85% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 104 106 | 63.78 | 66.2% | 1 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 23 33 | 14.94 | 120.88% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 97 131 | 112.44 | 16.51% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 10 2 | 1.1 | 81.82% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 85 83 | 27.69 | 199.75% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 253 288 | 240.92 | 19.54% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 28 5 | 2.65 | 88.68% | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 47 | 35.51 | 32.36% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 5 | 7.6 | -34.21% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 18 | 4.58 | 293.01% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 39 42 | 21.85 | 92.22% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 33 | n/a | n/a | 7 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 25 | 6.28 | 298.09% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 45 42 | 13.22 | 217.7% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 40 | n/a | n/a | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 18 | 3.93 | 358.02% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 8 | 0.86 | 830.23% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | 5.55 | 296.4% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 47 | 7.03 | 568.56% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 9 | n/a | n/a | 1 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16 | 9.21 | 73.72% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 123 | 17.2 | 615.12% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 192 134 | 24 | 458.33% | 3 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 121 | n/a | n/a | 1 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 10 | n/a | n/a | 1 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 57 68 | n/a | n/a | 2 | Oct 22, 2018 |